Literature DB >> 18941120

Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response.

Eliot Marston1, Victoria Weston, Jennifer Jesson, Esther Maina, Carmel McConville, Angelo Agathanggelou, Anna Skowronska, Katie Mapp, Katrin Sameith, Judith E Powell, Sarah Lawson, Pamela Kearns, Francesco Falciani, Malcolm Taylor, Tatjana Stankovic.   

Abstract

The molecular basis of different outcomes in pediatric acute lymphoblastic leukemia (ALL) remains poorly understood. We addressed the clinical significance and mechanisms behind in vitro cellular responses to ionizing radiation (IR)-induced DNA double-strand breaks in 74 pediatric patients with ALL. We found an apoptosis-resistant response in 36% of patients characterized by failure to cleave caspase-3, -7, -9, and PARP1 by 24 hours after IR and an apoptosis-sensitive response with the cleavage of the same substrates in the remaining 64% of leukemias. Resistance to IR in vitro was associated with poor early blast clearance at day 7 or 15 and persistent minimal residual disease (MRD) at day 28 of induction treatment. Global gene expression profiling revealed abnormal up-regulation of multiple prosurvival pathways in response to IR in apoptosis-resistant leukemias and differential posttranscriptional activation of the PI3-Akt pathway was observed in representative resistant cases. Importantly, pharmacologic inhibition of selected prosurvival pathways sensitized apoptosis-resistant ALL cells to IR in vitro. We suggest that abnormal prosurvival responses to DNA damage provide one of the mechanisms of primary resistance in ALL, and that they should be considered as therapeutic targets in children with aggressive disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941120     DOI: 10.1182/blood-2008-03-142950

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia.

Authors:  B G Mar; L Bullinger; E Basu; K Schlis; L B Silverman; K Döhner; S A Armstrong
Journal:  Leukemia       Date:  2012-03-01       Impact factor: 11.528

2.  STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.

Authors:  Fatih M Uckun; Sanjive Qazi; Hong Ma; Lisa Tuel-Ahlgren; Zahide Ozer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-29       Impact factor: 11.205

3.  SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Fatih M Uckun; Sanjive Qazi
Journal:  J Cancer Ther       Date:  2014-01

4.  Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.

Authors:  Victoria J Weston; Wenbin Wei; Tatjana Stankovic; Pamela Kearns
Journal:  Exp Hematol       Date:  2018-04-12       Impact factor: 3.084

Review 5.  Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers.

Authors:  Nilay Shah
Journal:  Cancer Drug Resist       Date:  2019-09-19

6.  BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia.

Authors:  D Da Costa; A Agathanggelou; T Perry; V Weston; E Petermann; A Zlatanou; C Oldreive; W Wei; G Stewart; J Longman; E Smith; P Kearns; S Knapp; T Stankovic
Journal:  Blood Cancer J       Date:  2013-07-19       Impact factor: 11.037

Review 7.  Advances in genome studies in plants and animals.

Authors:  R Appels; J Nystrom-Persson; G Keeble-Gagnere
Journal:  Funct Integr Genomics       Date:  2014-03-14       Impact factor: 3.410

8.  A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia.

Authors:  William E Evans; Kenan Onel; Russell O Bainer; Matthew R Trendowski; Cheng Cheng; Deqing Pei; Wenjian Yang; Steven W Paugh; Kathleen H Goss; Andrew D Skol; Paul Pavlidis; Ching-Hon Pui; T Conrad Gilliam
Journal:  Cancer Manag Res       Date:  2017-09-13       Impact factor: 3.989

9.  Nucleotide excision repair is a predictor of early relapse in pediatric acute lymphoblastic leukemia.

Authors:  Omar M Ibrahim; Homood M As Sobeai; Stephen G Grant; Jean J Latimer
Journal:  BMC Med Genomics       Date:  2018-10-30       Impact factor: 3.063

10.  Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination.

Authors:  Nina M S Gustafsson; Katarina Färnegårdh; Nadilly Bonagas; Anna Huguet Ninou; Petra Groth; Elisee Wiita; Mattias Jönsson; Kenth Hallberg; Jemina Lehto; Rosa Pennisi; Jessica Martinsson; Carina Norström; Jessica Hollers; Johan Schultz; Martin Andersson; Natalia Markova; Petra Marttila; Baek Kim; Martin Norin; Thomas Olin; Thomas Helleday
Journal:  Nat Commun       Date:  2018-09-24       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.